China a priority for Novartis’ Narasimhan
Novartis CEO Narasimhan on the pharma’s plans in China, BD&L and reimbursement
Novartis CEO Vasant Narasimhan says capitalizing on the rise of China, by prioritizing drug launches in the country, will be a key pillar of the pharma’s strategy over the next few years.
A second pillar will be M&A that builds depth in Novartis’ core therapeutic areas.
BioCentury recently sat down with Narasimhan for a broad-ranging discussion on the state of biopharma, and his outlook for the industry and Novartis. Last week, in the first of a three-part series from that conversation, he shared his perspectives on drug pricing and other policy issues (see “Narasimhan Calls for Value-based Pricing -- and Access”).
In this second installment, Narasimhan discusses Novartis’ growth strategy and offers his views on drug development and reimbursement in China, as well as the need for reimbursement reform in the U.S. The third installment, to be published in the coming weeks, will feature his comments on innovation and digital health.
China’s across-the-board reforms to regulation, manufacturing, reimbursement and other areas of drug development have elevated the country to a key pillar of Novartis’ global drug development strategy. Narasimhan thinks that China’s policy changes are not without